The group will need longer-term data to justify its huge valuation.
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Novo moves into amyloidosis not long after Intellia made a splash here.
After several cancer failures Celldex tries its hand at autoimmune disease, and the market likes it.
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.